Chemed Corporation CHE
Composite 57/100; the shares have moved about 26% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 33/100 — a moderate mark against it.
Momentum ranks 72/100 — a moderate point in its favour. Balance-sheet strength ranks 70/100 — a moderate point in its favour. Quality ranks 68/100 — a moderate point in its favour.
Growth ranks 33/100 — a moderate mark against it. Income ranks 38/100 — a moderate mark against it. Valuation ranks 40/100 — a slight mark against it.
What the company does Chemed Corporation operates two segments: VITAS (hospice and palliative care) and Roto-Rooter (plumbing and water restoration). It serves patients and families with medical, spiritual, and emotional support primarily in the U.S.
Key financials ROE 25.6%, ROA 12.8%, ROCE 29.0%. Margins: gross 32.4%, operating 12.9%, net 10.2%. Revenue growth 1.6%, EPS growth -0.4%. Debt/Equity 0.35, interest coverage 101.36, current ratio 0.91.
Stock health Sideravia Overall 57.5 (average quality, fairly valued, positive momentum). Momentum: 3m 26.32%, 6m 23.96%, 12m 15.71%. RSI(14) 75.10 (overbought).
Price vs fair value The stock trades at a PREMIUM of 3.60% versus our fair-value estimate and a PREMIUM of 11.37% versus the analyst 12-month target. - Q2 2026 earnings beat and revenue growth cited as drivers (Zacks, StockStory). - Strong VITAS performance highlighted in earnings call (GuruFocus.com, MarketBeat). - Buyback activity increased amid activist pressure (Simply Wall St.).
Looking forward Forward P/E 20.96, PEG 0.63. Analysts note VITAS growth but flag Roto-Rooter marketing pressures. Valuation percentile 46.5/100 suggests near fair value.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.